Literature DB >> 21549784

Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge.

Waleed Mustafa1, Fetweh H Al-Saleem, Zidoon Nasser, Rebecca M Olson, Jeffrey A Mattis, Lance L Simpson, Matthias J Schnell.   

Abstract

We previously showed that rabies virus (RABV) virions are excellent vehicles for antigen presentation. Here, a reverse genetic approach was applied to generate recombinant RABV that express a chimeric protein composed of the heavy chain carboxyterminal half (HC50) of botulinum neurotoxin type A (BoNT/A) and RABV glycoprotein (G). To promote surface expression and incorporation of HC50/A into RABV virions, the RABV glycoprotein (G) ER translocation sequence, various fragments of RABV ectodomain (ED) and cytoplasmic domain were fused to HC50/A. The HC50/A chimeric proteins were expressed on the surface of cells infected with all of the recombinant RABVs, however, the highest level of surface expression was detected by utilizing 30 amino acids of the RABV G ED (HV50/A-E30). Our results also indicated that this chimeric protein was effectively incorporated into RABV virions. Immunization of mice with inactivated RABV-HC50/A-E30 virions induced a robust anti-HC50/A IgG antibody response that efficiently neutralized circulating BoNT/A in vivo, and protected mice against 1000 fold the lethal dose of BoNT/A.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21549784      PMCID: PMC3114282          DOI: 10.1016/j.vaccine.2011.04.045

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  50 in total

Review 1.  A two-phase model of B-cell activation.

Authors:  N Baumgarth
Journal:  Immunol Rev       Date:  2000-08       Impact factor: 12.988

Review 2.  Botulinum toxin as a biological weapon: medical and public health management.

Authors:  S S Arnon; R Schechter; T V Inglesby; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; J Hauer; M Layton; S Lillibridge; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; D L Swerdlow; K Tonat
Journal:  JAMA       Date:  2001-02-28       Impact factor: 56.272

3.  Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.

Authors:  Michael R Baldwin; William H Tepp; Christina L Pier; Marite Bradshaw; Mengfei Ho; Brenda A Wilson; Robert B Fritz; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

Review 4.  Clostridium botulinum: a bug with beauty and weapon.

Authors:  H D Shukla; S K Sharma
Journal:  Crit Rev Microbiol       Date:  2005       Impact factor: 7.624

5.  Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice.

Authors:  John S Lee; Jennifer L Groebner; Angela G Hadjipanayis; Diane L Negley; Alan L Schmaljohn; Susan L Welkos; Leonard A Smith; Jonathan F Smith
Journal:  Vaccine       Date:  2006-06-21       Impact factor: 3.641

6.  A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection.

Authors:  H D Foley; J P McGettigan; C A Siler; B Dietzschold; M J Schnell
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

Review 7.  Development of vaccines for prevention of botulism.

Authors:  M P Byrne; L A Smith
Journal:  Biochimie       Date:  2000 Sep-Oct       Impact factor: 4.079

8.  Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli.

Authors:  M A Clayton; J M Clayton; D R Brown; J L Middlebrook
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

9.  Rabies virus glycoprotein as a carrier for anthrax protective antigen.

Authors:  Mary Ellen Smith; Martin Koser; Sa Xiao; Catherine Siler; James P McGettigan; Catherine Calkins; Roger J Pomerantz; Bernhard Dietzschold; Matthias J Schnell
Journal:  Virology       Date:  2006-07-03       Impact factor: 3.616

10.  Recombinant rabies virus as potential live-viral vaccines for HIV-1.

Authors:  M J Schnell; H D Foley; C A Siler; J P McGettigan; B Dietzschold; R J Pomerantz
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  11 in total

1.  Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens.

Authors:  Renata da Fontoura Budaszewski; Andrew Hudacek; Bevan Sawatsky; Beate Krämer; Xiangping Yin; Matthias J Schnell; Veronika von Messling
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

2.  Enhancing toxin-based vaccines against botulism.

Authors:  Amanda Przedpelski; William H Tepp; Madison Zuverink; Eric A Johnson; Sabine Pellet; Joseph T Barbieri
Journal:  Vaccine       Date:  2018-01-04       Impact factor: 3.641

Review 3.  Rhabdoviruses as vectors for vaccines and therapeutics.

Authors:  Gabrielle Scher; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2020-10-29       Impact factor: 7.090

4.  A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence.

Authors:  Amy B Papaneri; Christoph Wirblich; Jennifer A Cann; Kurt Cooper; Peter B Jahrling; Matthias J Schnell; Joseph E Blaney
Journal:  Virology       Date:  2012-08-11       Impact factor: 3.616

5.  Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.

Authors:  Amy B Papaneri; Christoph Wirblich; Kurt Cooper; Peter B Jahrling; Matthias J Schnell; Joseph E Blaney
Journal:  Vaccine       Date:  2012-08-08       Impact factor: 3.641

Review 6.  Viral and Synthetic RNA Vector Technologies and Applications.

Authors:  Juliane W Schott; Michael Morgan; Melanie Galla; Axel Schambach
Journal:  Mol Ther       Date:  2016-07-05       Impact factor: 11.454

7.  Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo.

Authors:  Andrew W Hudacek; Fetweh H Al-Saleem; Mallory Willet; Travis Eisemann; Jeffrey A Mattis; Lance L Simpson; Matthias J Schnell
Journal:  Mol Ther Methods Clin Dev       Date:  2014-10-01       Impact factor: 6.698

8.  Immunomodulatory Effects of the Meretrix Meretrix Oligopeptide (QLNWD) on Immune-Deficient Mice.

Authors:  Wen Zhang; Lei Ye; Fenglei Wang; Jiawen Zheng; Xiaoxiao Tian; Yan Chen; Guofang Ding; Zuisu Yang
Journal:  Molecules       Date:  2019-12-05       Impact factor: 4.411

Review 9.  Vaccines against Botulism.

Authors:  Grace Sundeen; Joseph T Barbieri
Journal:  Toxins (Basel)       Date:  2017-09-02       Impact factor: 4.546

Review 10.  Antibodies and Vaccines against Botulinum Toxins: Available Measures and Novel Approaches.

Authors:  Christine Rasetti-Escargueil; Michel R Popoff
Journal:  Toxins (Basel)       Date:  2019-09-12       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.